A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper, S., Overkamp, F., Moehler, M., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Hegewisch-Becker, S., Seehofer, D., Bechstein, W., Heike, M., Voehringer, M., Heinemann, V., Greil, R., Geissler, M., Lordick, F., Peeters, M., Van Cutsem, E., Galle, P.R., Schimanski, C.C., 2013.

J Clin Oncol 31(suppl; abstr TPS3124). doi: 10.1200/jco.2013.31.15_suppl.tps3124

Studie: LICC; Indikation: Kolorektalkarzinom; Jahr: 2013; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com